Compare Rent the Runway Inc (RENT) vs 10X Genomics Inc (TXG) Price & Performance

RENT trades at $3.10, down 1.9% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported Q1 2026 revenue growth of 29.2% year-over-year to $89.9 million, beating expectations, but net income remains negative at -$69.9 million for 2025. Leadership transition is underway with the CEO stepping down in May 2026, while the balance sheet shows negative equity of -$182.5 million and high debt levels.

The outlook is mixed: strong revenue growth and low valuation ratios (P/E 0.41, P/S 0.17) suggest upside potential, but persistent losses, negative equity, and high leverage pose significant risks. Analyst consensus is cautious with 42% buy ratings, highlighting the stock's speculative nature amid operational challenges and debt concerns.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.